Learning Objectives:

1. Review the accumulated clinical experience in treating IPF with antifibrotics.

2. Review the current evidence behind the use of antifibrotic agents in SSc-ILD.

3. Critically evaluate the medical benefits with respect to potential side effects and increase in medical costs associated with the use of antifibrotic agents in SSc.


Session date: 
Tuesday, October 22, 2019 - 8:30am to 9:30am
  • 1.00 AMA PRA Category 1 Credit™
  • 1.00 Participation

Please login or create an account to proceed.
Speaker Name: 
Iazsmin Bauer Ventura, M.D., M.Sc.